Science

The ImmunoGram Drug Discovery Engine is a cascade of activities including target identification and validation, clinical bio-informatics and druggability evaluation. Our platform is based on the “Cancer Immunogram”, a framework published by leading scientists including Flindr’s co-founder Prof. Christian Blank, which describes seven parameters of host and tumor interactions as observed in the clinic from patients treated with immunotherapy.

Our collaborators, the NCI and VIB, perform high-throughput screening in robust laboratory models that recapitulate the heterogeneity in immune and cancer parameters, followed by rigorous target validation in animal and cancer models. We use clinical bio-informatics to identify clinical application(s) and potential patient responder biomarkers. Proprietary biochemical, cellular and target/pathway engagement assays are developed in-house.

The Immunogram Drug Discovery Engine identifies novel therapeutics that have immune modulating activities as well as highly targeted cancer-centric therapeutics.